Novartis is said to be abandoning Ionis heart drug after late-stage trial setback
TBE/iStock Editorial via Getty Images
Novartis (NVS) is largely abandoning the development of a heart disease therapy discovered by Ionis Pharmaceuticals (IONS) after the RNA-targeting therapy failed in a late-stage trial last September, Bloomberg reported on Saturday.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.